Akebia Therapeutics
Anna Zuk has a strong background in scientific research and leadership in the biotechnology and medical field. Anna has extensive experience in renal injury and fibrosis research, as well as in developing and executing scientific strategies for pipeline development. Throughout their career, Anna has secured substantial funding from NIH and has successfully implemented cross-functional collaborations. Anna has also held teaching positions at Harvard Medical School.
Anna Zuk has completed a Doctor of Philosophy (PhD) in Cell Biology and Anatomy from Loyola University Chicago Stritch School of Medicine. Anna has also pursued further education as an NIH Postdoctoral Fellow in the laboratory of Elizabeth D. Hay, M.D. at Harvard Medical School, focusing on Cell and Developmental Biology.
Akebia Therapeutics
3 followers
Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology.